Tuberculosis DNA vaccine - Merck & Co

Drug Profile

Tuberculosis DNA vaccine - Merck & Co

Alternative Names: DNA-Ag85A vaccine

Latest Information Update: 24 May 2006

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Vical
  • Class DNA vaccines; Gene therapies; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 24 May 2006 No development reported - Preclinical for Tuberculosis in USA (IM)
  • 20 Aug 2002 This vaccine is still in active development
  • 23 Nov 1999 A preclinical study has been added to the Bacterial Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top